Skip to main content

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Completed · Phase 3 · NCT04225871

Conditions: Generalized Myasthenia Gravis

At a glance

Research payments reported, 2025
$1.1M
U.S. investigators named
28
Sites paid
28
Planned or actual enrollment
200

About the trial

Sponsor
UCB Biopharma SRL
Tested
zilucoplan (RA101495) (drug)
Dates
Started 2019-12-23; completion 2026-07-31
Results posted
Not yet

The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

From ClinicalTrials.gov, last updated 2026-10-16. Full record, eligibility and contacts (opens in a new tab)

Industry funding

UCB SA reported $1.1M in research payments for this study in 2025 (29 payments).

Products named: Zilbrysq

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.